anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Cosmetic use of a vitamin K (I) or its derivatives or precursors or an extract that containing (I) in a composition (A) as an agent to improve and/or repair the barrier function of skin or semi-mucous membranes. An independent claim is also included for a cosmetic process to improve comfort of the skin, scalp or semi-mucous membranes or to fight against the appearance of microscopic cracks or of microchaps comprising administration and/or application of (A) to the skin, scalp or mucous membranes. ACTIVITY : Dermatological. MECHANISM OF ACTION : Transglutaminase K activator. The ability of (I) to activate transglutaminase K was tested. The results showed that the percentage activation of transglutaminase K by (I) at 10-7> M was 95%.
Late SCS treatment. After 2 weeks without SCS, randomization to either of two study arms: Group B starting with no SCS for a period of six weeks (A) followed by a period of active SCS (on-period for 6 weeks). Thereafter, free stimulation for 12 weeks, followed by a concluding 2 sweeks of no SCS.
Transcranial magnetic stimulation (TMS) is a non-invasive therapeutic technique used to stimulate regions of the brain using magnetic pulses. Repeated TMS delivers sequences of pulses for multiple days in a row and is an approved treatment for several psychiatric conditions. Deep TMS (dTMS) is a new technique that uses modified magnetic Hesed coils (H-coils) to stimulate deeper regions of the brain and has been FDA- and Health Canada-approved for major depressive disorder (MDD), obsessive-compulsive disorder, smoking cessation, and anxious-depression in adults. For older adults (60+), traditional rTMS has also shown efficacy for MDD (60+) and one RCT has found benefit for the H1 dTMS coil, but no trials have examined the H4 and H7 coils in this population. This innovative pilot study will explore dTMS feasibility and tolerability (i.e., side effects, impacts on mental health and cognition) of these two dTMS coils (H4, targeting insula and H7, targeting anterior cingulate cortex) in older adults with depression. The pilot will provide critical preliminary data for a future trial comparing these novel interventions to the H1-coil and a sham stimulation control. There is sparse literature examining the effects of dTMS on cognition, as measured by neuropsychological testing, and brain activity, as measured by electroencephalogram (EEG), while comparing different dTMS H-coils. Therefore, a second feature of the design includes assessing both domains over the course of treatment. The results will lay the foundation for a future randomized controlled trial examining the efficacy and mechanisms of one or both of these novel forms of neurostimulation for MDD in older adults.
Supine Hypertension: The most potentially serious adverse reaction associated with Midodrine hydrochloride therapy is marked elevation of supine arterial blood pressure (supine hypertension). Systolic pressure of about 200 mmHg were seen overall in about 13.4% of patients given 10 mg of Midodrine hydrochloride. Systolic elevations of this degree were most likely to be observed in patients with relatively elevated pre-treatment systolic blood pressures (mean 170 mmHg). There is no experience in patients with initial supine systolic pressure above 180 mmHg, as those patients were excluded from the clinical trials. Use of Midodrine hydrochloride in such patients is not recommended. Sitting blood pressures were also elevated by Midodrine hydrochloride therapy. It is essential to monitor supine and sitting blood pressures in patients maintained on Midodrine hydrochloride. Uncontrolled hypertension increases the risk of cardiovascular events, particularly stroke.
VELCADE at 1.3 mg/m2 IVP on days 1, 4, 8 and 11 in combination with high-dose cyclophosphamide at 2.0 g/m2 on day 4. G-CSF is given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day. Pheresis will commence once ANC of 1.5 is reached.
This step will be done twice in two different cycles In each cycle: luteal phase priming using combined contraceptive pills from day 21 of the previous cycle for one week by Gynera tab. Controlled ovarian hyper-stimulation using antagonist protocol will be used. Stimulation with 225-375 IU of gonadotropins will be started day 2-3 of menses after vaginal ultrasound confirming the absence of ovarian cysts. Cetrotide ampule will be given daily as the biggest oocyte reaches size 14 mm. Decapeptyl ampules 0.2 mg will be administered when leading follicle \>18 mm in diameter. While in the second cycle HCG triggering (Choriomon)in a dose of 10,000 IU will be administered when the leading follicle \>18 mm in diameter. Embryo transfer will be scheduled on Day 3, 4 or 5 with maximum number of 3 class A embryos whether of cleavage or blastocyst stage that will be a mixture of the thawed embryos of the first cycle and fresh embryos of the second cycle.
If picked for this group, you will attend study meetings with a weight management counselor. During the second trimester study meetings occur 4 times per month. During the third trimester you will attend study meetings 2 times per month. These meetings will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs/therapeutic agents within the GI tract. Many embodiments provide swallowable devices for delivering the agents. Particular embodiments provide a swallowable device for delivering drugs into the intestinal wall (IW). Embodiments also provide preparations including a plurality of glucose regulating compounds (GRC) that are configured to be contained within the capsule, advanced from the capsule into the IW and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW. Particular embodiments provide therapeutic preparations comprising insulin, GLP-1 and a third GRC where the third compound interacts with insulin or GLP-1 to produce an enhanced therapeutic effect in the patient.
Mitochondrial dysfunction and associated inflammatory signaling are pivotal in both aging and in Alzheimer's disease (AD). Studies have also shown that hypothalamic function is affected in AD. The hypothalamus may be a target for AD drugs given that mitochondrial alterations are observed in the hypothalamus. This study investigated how age and sex affect mitochondrial bioenergetics and inflammatory signaling in the hypothalamic mitochondria of 3xTg and control mice at 2, 6, and 13 months, aiming to enhance our understanding of these processes in aging and AD. Parameters included oxygen consumption rates, expression levels of subunits comprising mitochondrial complexes I-V, the enzymatic activity of cytochrome c oxidase (COX), transcription factors associated with inflammation such as NF-κB, pIκB-α, Nrf2, and other inflammatory biomarkers. Hypothalamic mitochondrial dysfunction was observed in 3xTg females as early as 2 months, but no changes were detected in 3xTg males until 6 months of age. In 3xTg mice, subunit expression levels for mitochondrial complexes I-II were significantly reduced in both sexes. Significant sex-based differences in COX activity were also observed at 13 months of age, with levels being lower in females compared to males. In addition, significant sex differences were indicated in NF-κB, pIκB-α, Nrf2, and other inflammatory biomarkers at different age groups during normal aging and AD progression. These findings highlight important sex differences in hypothalamic bioenergetics and inflammation, offering insights into potential new targets for preventing and/or treating AD.
PROBLEM TO BE SOLVED: To obtain a hair growing and restoring agent hawing a hair restoring function such as excellent prevention against loss of hair, chromogenic effect, etc., by combining an extract of an innocuous and stable specific crude drug with a cell activator or a promoter for circulation of blood. SOLUTION: This agent is prepared by combining one or more than two kinds of substances selected from a group consisting of an extract of Houttuynid cordata (Saururaceae Houttuynid cordata), and extract of Lindera strychinifolia F. Viel (Lauraceae Lindera strychinifolia F. Viel), an extract of bark of cherry tree (Rosaceae Prunus jamasakura Sieb. et Koizumi) and carnitine chloride with one or more than two kinds of cell activators and promoters for circulation of blood. As the cell activator, pantothenic acid and its derivative, a sensitizing dye 301, an extract of ginseng, biotin, etc., are illustrated. The blending amount is about 0.001-10weight%. As the promoter for circulation of blood, e.g. carpronium chloride, an extract of Swertia japonica, a tincture of Capsicum annum, etc.. are illustrated. The blending amount is about 0.001-10weight%.  Moreover, the blending amount of the above crude drug is about 0.001-10weight%.
Annexin A2 (ANXA2) is a widely reported oncogene. However, the mechanism of ANXA2 in esophageal cancer is not fully understood. In this study, we provided evidence that ANXA2 promotes the progression of esophageal squamous cell carcinoma (ESCC) through the downstream target threonine tyrosine kinase (TTK). These results are consistent with the up-regulation of ANXA2 and TTK in ESCC. In vitro experiments by knockdown and overexpression of ANXA2 revealed that ANXA2 promotes the progression of ESCC by enhancing cancer cell proliferation, migration, and invasion. Subsequently, animal models also confirmed the role of ANXA2 in promoting the proliferation and metastasis of ESCC. Mechanistically, the ANXA2/TTK complex activates the Akt/mTOR signaling pathway and accelerates epithelial-mesenchymal transition (EMT), thereby promoting the invasion and metastasis of ESCC. Furthermore, we identified that TTK overexpression can reverse the inhibition of ESCC invasion after ANXA2 knockdown. Overall, these data indicate that the combination of ANXA2 and TTK regulates the activation of the Akt/mTOR pathway and accelerates the progression of ESCC. Therefore, the ANXA2/TTK/Akt/mTOR axis is a potential therapeutic target for ESCC.
Fascial distortion will be applied to 27 participants where the tip of the thumb worms its way through the peripheral tissue until it rests on the distortion. Force is focused directly on the most painful spot until the provider feels like a button-slipping-into-a-buttonhole. After this, neural mobilization will be given as a stander treatment.
PURPOSE: To provide a system enabling previously determined controlled medicinal administration through the skin or mucous membrane, by incorporating an active medicinal ingredient and diffusion promoter in at least one of laminated elastomeric matrices. CONSTITUTION: This administration system consists of at least tow laminated elastomeric matrices each having both previously determined thickness and area (pref. silicone elastomer matrix). In this system, an active medicinal ingredient (pref. β2 -adrenaline-agonistic receptor agonist, esp. albuterol) is dispersed in at least one of the matrices, and a diffusion promoter (pref. n-hydrocarbon alcohol, esp. n-dodecanol) is dispersed in at least one of the above matrices as well. Furthermore, this system is additionally formulated with a plasticizer (pref. glycerol), solubilizing agent (pref. n-hexanol), and curing catalyst for the elastomer.
BACKGROUND: The rotational change after using a flexible intramedullary (IM) nail for femoral shaft fractures has been a concern for many surgeons. Recently, a statistical shape model (SSM) was developed for the three-dimensional reconstruction of the femur from two-dimensional plain radiographs. In this study, we measured postoperative femoral anteversion (FAV) in patients diagnosed with femoral shaft fractures who were treated with flexible IM nails and investigated age-related changes in FAV using the SSM.
METHODS: This study used radiographic data collected from six regional tertiary centers specializing in pediatric trauma in South Korea. Patients diagnosed with femoral shaft fractures between September 2002 and June 2020 and patients aged < 18 years with at least two anteroposterior (AP) and lateral (LAT) femur plain radiographs obtained at least three months apart were included. A linear mixed model (LMM) was used for statistical analysis.
RESULTS: Overall, 72 patients were included in the study. The average patient age was 7.6 years and the average follow-up duration was 6.8 years. The average FAV of immediate postoperative images was 27.5 ± 11.5°. Out of 72 patients, 52 patients (72.2%) showed immediate postoperative FAV greater than 20°. The average FAV in patients with initial FAV > 20° was 32.74°, and the LMM showed that FAV decreased by 2.5° (p = 0.0001) with each 1-year increase from the time of initial trauma.
CONCLUSIONS: This study explored changes in FAV after femoral shaft fracture using a newly developed technology that allows 3D reconstruction from uncalibrated 2D images. There was a pattern of change on the rotation of the femur after initial fixation, with a 2.5° decrease of FAV per year.
Babies in the control group will receive physical contention with administration of sucrose two minutes before carrying out the venipuncture procedure (usual care). Venipuncture will be performed with 22G extraction needles, or peripheric venous catheter. During the puncture the eyes will not be covered, and monitor alarms and devices be not be silenced.
The study design will be a randomized parallel study consisting of a 4-week period during which each participant will be assigned to one of the two food groups. Participants in each group will be provided with a daily provision of a chosen sugar-sweetened beverage or savory snack to incorporate into their usual dietary pattern. The main outcome is dietary intake, specifically energy intake gathered by 24 hour dietary recalls. Secondary outcomes include measured body weight / BMI. The participant will be blinded to the main outcome so as not to affect the results. To do this they will be told the rationale for the study is to examine the effect of discretionary food sources on perceived health status and provided a standard, valid short questionnaire (SF-12) at the beginning, middle and end of each period. Investigators will estimate the energy intake necessary for weight maintenance of the subject based upon a standard approach and equation that accounts for the participant's age, sex, body size, and activity level. The subject will be provided with approximately 15-20% of their estimated daily energy needs in the form of a sugar-sweetened beverage or savory snack of their choice during one period and will be asked to incorporate this into their usual dietary pattern each day for 4 weeks. During the 4 week period the subject will be randomly prompted to complete five, 24-hour dietary recalls using an online tool. They will also be asked to fill out a short physical activity questionnaire during the intervention periods and a short questionnaire on perceived health (SF-12). They will have their weight, height, and waist circumference measured at the beginning and end of the period.
1. Technical Result Increase in efficiency of rumor treatment. 2. Essence A humanized anti-lymphotoxin-beta receptor (LT-beta-R) antibody is provided. The antibody comprises a heavy and light chain hypervariable domain sequence (CDR) defined by amino acid residues and a coding sequence. The humanized antibody is used for production of pharmaceutical composition with the purpose of reducing the advancement, severity or effects of neoplasia, reducing solid tumors and treating solid tumors in a subject. 3. Field of Application Medicine, immunology.
INTRODUCTION: Familial Mediterranean fever (FMF) is a genetic disease leading to recurrent episodes of inflammation. Two pathogenic variants are required for classical disease, but the disease can occur in heterozygous patients. Patients are treated continuously with colchicine to prevent amyloid A (AA) amyloidosis, including heterozygous patients who display a moderate form of FMF and rarely develop AA amyloidosis. The need for lifelong colchicine treatment in heterozygous FMF is therefore controversial. We aimed to characterise genotype-specific levels of inflammatory biomarkers, and to focus on heterozygous patients who discontinued colchicine.
METHODS: All patients with FMF from the European databases AIDnet and JIRcohort who received colchicine during follow-up were included. Demographics, C reactive protein (CRP), serum amyloid A (SAA), S100A8/A9 and S100A12 levels, leucocyte and neutrophil counts were extracted. Visits were classified as active, subclinical or inactive according to symptoms, CRP and SAA levels.
RESULTS: Data from 747 patients were extracted (233 homozygous, 201 compound heterozygous, 224 heterozygous patients, 49 heterozygous with one class III variant and 40 compound heterozygous with two class III variants). During active visits, all biomarker levels were higher compared with inactive visits (p<0.001). Heterozygous patients showed lower levels of CRP, SAA, S100A8/A9 and S100A12 during inactive and subclinical visits than patients with two class IV-V variants. Colchicine was discontinued in 52 heterozygous patients and reintroduced in 23 of them (44%).
CONCLUSION: S100A8/A9 and S100A12 proteins are biomarkers that can be used to assess disease activity. Heterozygous patients have lower levels of inflammatory biomarkers and some of them can sustainably discontinue colchicine treatment.
The invention discloses an enteric preparation of erigeron breviscapus extractive. The enteric preparation is made by the erigeron breviscapus extractive and medical accessories of the enteric preparation. The enteric preparation comprises, by weight, 1 part of erigeron breviscapus extractive and 2-19 parts of accessory. The erigeron breviscapus ethanol extractive serves as the raw material, and the erigeron breviscapus enteric preparation is prepared through an enteric preparation technology after the accessories are added. The experiment result shows that the dissolution rate of the enteric preparation in artificial gastric fluid is lower than 5 percent, and the enteric preparation is disintegrated and released in artificial intestinal fluid. According to the preparation, the stimulation of phenolic acid ingredients in erigeron breviscapus to the gastric mucosa can be effectively avoided, the technology operation is simple, and the enteric preparation is suitable for industrial production.
A biologically active polysaccharide complex is prepared by proteolysing organisms of a pseudomonas species, and separating the polysaccharide from the proteolysed cellular material by dialysis, using a membrane having a porosity sufficient to pass 75 to 90 per cent of similarly proteolysed crystalline bovine albumin.  The bacteria which may be treated include the azotobacteriaceae, Rhizobiaceae, Neisseriaceae, Lactobacteriaceae, Achromobacteriaceae, Entorobacteriaceae, Bacteriaceae, Bacillaceae, Parvobacteriaceae, Brucelleae, Nitrobacteriaceae, Micrococcaceae and Corynebacteriaceae, specific examples being Eubacteriineae, Proteus vulgaris, B. subtilis, Salmonella typhosa, Serratia marcescens, Escherichia coli, Enterobactericeae, Azobacter chroococcum, Chromobacterium violaceum, Neisseria catarrhalis, Alcaligenes faecalis, and B. mycoides.  The proteolysis may be effected by means of trypsin, pancreatin, papain, polidase-5, a fish enzyme, or protease.  The dialysis membrane may be made from cellulose sausage casing, regenerated cellulose sheet, or wet regenerated cellulose gel film tubing.  After the bacteria have been grown and harvested, they may be thermally killed before the proteolysis which may be carried out in the presence of a preservative such as toluene or thimerosal.  The product is preferably buffered at a pH of 5.5 to 8.5 with for example a lactate or citrate buffer.  After dialysis the retained active material may be centrifuged or filtered and then diluted for use or dried for storage.
Background: Vibrio vulnificus infections develop rapidly and have high mortality and disability rates. Vibrio vulnificus can cause local wound infection, gastroenteritis, or septicemia. Case Presentation: In this case, an 86-year-old male was accidentally stabbed in the middle of his right thumb while cleaning whitewater fish and came to the emergency department with high fever and painful swelling of the right hand. Physical examination revealed hemorrhagic bullae in the right hand. Emergency surgery and bacterial culture were performed. Because of timely antibiotic use and surgical treatment, the patient eventually recovered and was discharged from the hospital. Conclusions: This case suggests that the possibility of Vibrio vulnificus should be considered in cases of severe infection of the extremities, even without a history of seafood consumption or seawater exposure. Early recognition, rational choice of antibiotic agents, and timely wound debridement can substantially improve the prognosis of patients and reduce mortality.
A preparation for liquifying mucus or reducing its viscosity by biochemical oxidation is obtained by mixing one or more derivatives of lactic acid capable of acting as hydrogen donators and which are substrates of lactic dehydrogenase, with one or more per-compounds which are capable of acting as the corresponding hydrogen acceptors. The preparations may be applied in the industrial treatment of dead animal or vegetable tissues containing mucus, e.g. in treating animal intestines in the manufacture of sausage skins.  According to one example calcium-sodium lactate is mixed with sodium perforate and liquid paraffin.  According to a further example calcium lactate is mixed with magnesium peroxide and glycerin.  The mucolytic effect of the preparations is improved by the addition of a ferrous salt. They may also contain disinfecting, neutralizing or fermentation-checking agents with or without ethereal oils such as peppermint oil.  The first Provisional Specification describes also admixtures of hydrogen peroxide with lactic acid and ferrous sulphate, and of sodium peroxide with magnesium lactate, ferrous chloride and paraffin.  The second Provisional Specification refers also to the employment of oxybutyric acid and ascorbic acid as hydrogen donators.ALSO:A preparation for liquifying mucus or reducing its viscosity by biochemical oxidation is obtained by mixing one or more derivatives of lactic acid capable of acting as hydrogen donators and which are substrates of lactic dehydrogenase, with one or more percompounds which are capable of acting as the corresponding hydrogen acceptors. The preparations may be applied as a douche to diseased mucus membranes, as a mouth wash or gargle or in the form of tooth-cleaning pastes or powders.  According to one example, calcium-sodium lactate is mixed with sodium perborate and liquid paraffin.  According to a further example calcium lactate is mixed with magnesium peroxide and glycerin. The mucolytic effect of the preparations is improved by the addition of a ferrous salt.  They may also contain the usual bases of dentifrices, and disinfecting, neutralising or fermentation-checking agents with or without ethereal oils such as peppermint oil.  The first Provisional Specification describes also admixtures of hydrogen peroxide with lactic acid and ferrous sulphate, and of sodium peroxide with magnesium lactate, ferrous chloride and paraffin.  The second Provisional Specification refers also to the employment of oxybutyric acid and ascorbic acid as hydrogen donators.